Negma Group has converted 220 convertible bonds in Oxurion resulting in a EUR 550,000 capital increase. This is part of Negma Group’s EUR 30 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5 billion.
Leuven, BELGIUM – July 29, 2022 – 07.00 PM CET – In accordance with article 15 of the Belgian Act of May 2, 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, Oxurion NV (Euronext Brussels: OXUR) (the “Company” or “Oxurion”), announces the below information, following the issuance of 1,447,368 new ordinary shares on July 6, 2022, for a total amount of EUR 550,000, as the result of the conversion of 220 convertible bonds pursuant to the Capital Commitment entered into with Negma Group.
Following completion of the capital increase through the conversion of the convertible bonds, the total number of shares issued by Oxurion amounts to 51,268,557 outstanding ordinary shares carrying voting rights (compared to 49,821,189 outstanding ordinary shares previously). This number will be used as the denominator for the calculation of the percentages of shareholdings.
Therefore, Oxurion publishes the following updated information:
| 70,006,161.32 | |
|
51,268,557 |
|
|
